|
시장보고서
상품코드
1467832
황반변성 치료 시장 보고서 : 유형별, 단계별, 투여 경로별, 최종사용자별, 지역별(2024-2032년)Macular Degeneration Treatment Market Report by Type, Stage of Disease, Route of Administration, End User, and Region 2024-2032 |
||||||
황반변성 치료 세계 시장 규모는 2023년 94억 달러에 달했습니다. 향후 IMARC Group은 2024-2032년 5.5%의 연평균 성장률(CAGR)을 보이며 2032년까지 154억 달러에 달할 것으로 예상하고 있습니다.
황반변성증은 신경 퇴행성 안질환으로 눈을 침범하여 시야의 중심부 흐려짐과 시력 저하를 유발합니다. 시야의 맹점, 시각 왜곡, 저조도 시력 저하가 특징입니다. 황반변성 치료법으로는 혈관신생억제제, 광역학 레이저 치료, 콘택트렌즈, 전이렌즈 등이 일반적으로 사용되고 있습니다. 레이저 치료는 안구의 환부에 전용 콘택트렌즈를 삽입해 혈관과 함께 레이저로 봉합하는 방법입니다. 혈관 신생 억제제는 혈관이 막히거나 새는 것을 막기 위해 사용됩니다. 황반변성 치료를 제때에 받으면 시력을 개선하고 만성 실명의 위험을 최소화할 수 있습니다.
황반변성 치료 시장 동향:
노화 황반변성 및 비만 증가는 시장 성장을 촉진하는 주요 요인 중 하나입니다. 식습관의 변화와 좌식 생활습관의 증가는 황반변성 발병의 주요 원인으로 작용하고 있습니다. 또한, 스마트폰, 노트북, TV 사용의 증가로 인해 장시간 과도한 스크린 사용 시간이 늘어나는 것도 이 질환의 발생에 영향을 미치고 있습니다. 또한, 비정상적인 혈관 발달을 막기 위해 아데노부수체 바이러스(AAV)를 체내에 주입하는 망막 유전자 치료제의 시장 개척이 시장 성장을 견인하고 있습니다. 이와 함께 의료 인프라가 크게 개선되면서 시장 성장에 긍정적인 영향을 미치고 있습니다. 그 외의 요인으로는 혁신적이고 효과적인 의약품 개발을 위한 광범위한 R&D 활동과 공중보건 증진을 위한 다양한 정부 이니셔티브의 시행이 시장 성장을 촉진할 것으로 예상됩니다.
본 보고서에서 다루는 주요 질문들
- 2023년 세계 황반변성 치료 시장 규모는?
- 2024-2032년 세계 황반변성 치료 시장의 예상 성장률은?
- 황반변성 치료 세계 시장을 이끄는 주요 요인은 무엇인가?
- COVID-19가 세계 황반변성 치료 시장에 미치는 영향은?
- 황반변성 치료 세계 시장 유형별 분류는?
- 황반변성 치료 세계 시장 단계별 시장 현황은?
- 투여 경로별 황반변성 치료 세계 시장 현황은?
- 최종사용자별 황반변성 치료 세계 시장 현황은?
- 황반변성 치료 세계 시장 주요 지역은?
- 황반변성 치료 세계 시장 주요 진출 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 1차 정보
- 2차 정보
- 시장 추정
- 상향식 접근
- 하향식 접근
- 조사 방법
제3장 주요 요약
제4장 소개
- 개요
- 주요 산업 동향
제5장 황반변성 치료 세계 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 유형별
- 건성
- 습성
제7장 시장 내역 : 병기별
- 전기
- 중기
- 후기
제8장 시장 내역 : 투여 경로별
- 정맥내
- 유리체내
제9장 시장 내역 : 최종사용자별
- 병원
- 외래 수술 센터
- 기타
제10장 시장 내역 : 지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 인도네시아
- 기타
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 브라질
- 멕시코
- 기타
- 중동 및 아프리카
- 시장 동향
- 시장 내역 : 국가별
- 시장 예측
제11장 SWOT 분석
- 개요
- 강점
- 약점
- 기회
- 위협
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
- 개요
- 구매자의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 참여업체의 위협
- 대체품의 위협
제14장 가격 분석
제15장 경쟁 상황
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Aerie Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Bayer AG
- F. Hoffmann-La Roche Ltd
- Iveric Bio Inc.
- Novartis AG
- Panoptica
- Pfizer Inc.
- Phio Pharmaceuticals
- Regeneron Pharmaceuticals Inc.
- Regenxbio Inc.
- Santen Pharmaceutical Co. Ltd.
The global macular degeneration treatment market size reached US$ 9.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 15.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.5% during 2024-2032.
Macular degeneration is a neurodegenerative ocular disorder that affects the eyes and causes blurred or loss of vision in the center of the visual field. It is characterized by blind spots in the field of vision, visual distortions and inability to see in low light conditions. Some of the commonly used therapeutic techniques for macular degeneration includes anti-angiogenic drugs, photodynamic laser therapies, contact lenses and transitional lenses. Laser therapy involves the insertion of specialized contact lenses into the affected are of the eye, which are sealed by lasers along with the blood vessels. Anti-angiogenic drugs are used for preventing blockages and leakages in the blood vessels. Timely treatment of macular degeneration treatment can aid in enhancing vision and minimizing the risks of developing chronic blindness.
Macular Degeneration Treatment Market Trends:
The increasing incidences of age-related macular degeneration and obesity among the masses is one of the key factors driving the market growth. The changing dietary patterns and the rising adoption of sedentary lifestyles is leading to the development of macular degeneration. Additionally, the increasing utilization of smartphones, laptops and television, which is leading to prolonged and excessive screen time is also impacting the occurrence of the disorder. Moreover, the development of retinal gene therapies that involves the injection of adeno-associated virus (AAV) into the body for preventing the development of abnormal blood vessels is providing a thrust to the market growth. In line with this, significant improvements in the healthcare infrastructure is positively impacting the market growth. Other factors, including extensive research and development (R&D) activities for the development of innovative and effective drugs, along with the implementation of various government initiatives for promoting public health, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global macular degeneration treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, stage of disease, route of administration and end user.
Breakup by Type:
Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
Breakup by Stage of Disease:
Early Stage
Intermediate Stage
Late Stage
Breakup by Route of Administration:
Intravenous Route
Intravitreal Route
Breakup by End User:
Hospitals
Ambulatory Surgical Center
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Santen Pharmaceutical Co. Ltd.
Key Questions Answered in This Report
- 1. What was the size of the global macular degeneration treatment market in 2023?
- 2. What is the expected growth rate of the global macular degeneration treatment market during 2024-2032?
- 3. What are the key factors driving the global macular degeneration treatment market?
- 4. What has been the impact of COVID-19 on the global macular degeneration treatment market?
- 5. What is the breakup of the global macular degeneration treatment market based on the type?
- 6. What is the breakup of the global macular degeneration treatment market based on the stage of disease?
- 7. What is the breakup of the global macular degeneration treatment market based on the route of administration?
- 8. What is the breakup of the global macular degeneration treatment market based on the end user?
- 9. What are the key regions in the global macular degeneration treatment market?
- 10. Who are the key players/companies in the global macular degeneration treatment market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Macular Degeneration Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Dry Age-related Macular Degeneration
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Wet Age-related Macular Degeneration
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Stage of Disease
- 7.1 Early Stage
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Intermediate Stage
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Late Stage
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Route of Administration
- 8.1 Intravenous Route
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Intravitreal Route
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Ambulatory Surgical Center
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Aerie Pharmaceuticals Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.2 Bausch Health Companies Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Bayer AG
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 F. Hoffmann-La Roche Ltd
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.5 Iveric Bio Inc.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.6 Novartis AG
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Panoptica
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.8 Pfizer Inc.
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Phio Pharmaceuticals
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.10 Regeneron Pharmaceuticals Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Regenxbio Inc.
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 Santen Pharmaceutical Co. Ltd.
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
- 15.3.1 Aerie Pharmaceuticals Inc.
